Understand the source comparison
KPV for Rosacea Research: Comparison of Delivery Methods
Topical (aqueous solution) <50 μm (stratum corneum only) 1–5 mg per application, twice daily Low. Reconstitute and apply Minimal effect expected. Poor penetration Not recommended without penetration enhancer Topical (liposomal formulation) 200–300 μm (papillar
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Topical (aqueous solution)
- <50 μm (stratum corneum only)
- 1–5 mg per application, twice daily
- Low. Reconstitute and apply
- Minimal effect expected. Poor penetration
- Not recommended without penetration enhancer
- Topical (liposomal formulation)
- 200–300 μm (papillary dermis)
- 1–5 mg per application, once to twice daily
- Moderate. Requires lipid carrier preparation
- 4–6 weeks for erythema reduction
- Most practical for self-administered research use
- Subcutaneous injection
- Systemic distribution
- 35–350 mg per injection, twice weekly (human equivalent dose from animal models)
- Moderate. Sterile reconstitution required
- 2–4 weeks for inflammatory marker reduction
- Higher systemic exposure. Suitable for controlled research settings
- Topical with DMSO (5–10%)
- 150–200 μm (upper dermis)
- 1–5 mg per application, once daily
- Low-moderate. Mix DMSO into reconstituted solution
- 3–5 weeks
- Effective but DMSO carries odor and occasional irritation
- The liposomal formulation represents the best balance between efficacy and practical administration for rosacea research. Subcutaneous delivery achieves higher tissue concentrations but increases systemic exposure and requires clinical oversight most researchers working independently don't have.